Start-Up Quarterly Statistics, Q2 2011
This article was originally published in Start Up
Funding for biopharma start-ups nearly doubled from Q1 to Q2 2011, with a total of $251 million. The quarter saw increased investment in emerging markets, particularly in China. Biopharma start-ups scored many deals with Big Pharma, in several cases playing the role of licensee. And while M&A activity for the start-up set was limited to two deals, for each of those agreements the start-ups were the ones on the acquiring side scooping up assets from other companies.
You may also be interested in...
The Colorado cancer drug maker is seeking financing through the public capital markets.
Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.